| Name | GRGDSPK acetate |
| Description | GRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption. |
| In vitro | By measuring calcium content and 70 bonehnit area of tissue in parietal bones 18 days old isolated from pregnant Sprague-Dawley rats, we know that GRGDSPK (EMD 56574; RGD; 0.1-50 μM; for 4 days) inhibits mineralization in a dose-dependent manner.[1]
Treatment with GRGDSPK (10 and 50 μM; 4-day treatment) results in significant alterations in bone morphology, characterized by disruptions in the organization of osteoblasts and the mineralized matrix.[1]
In the presence of GRGDSPK peptide (RGD; 250 μM), added to the medium, the binding between integrins and fibronectin is effectively blocked, leading to a considerable increase in the average size of cell aggregates in wild-type cells.[2]
Addition of GRGDSPK (250 μM) leads to a significant reduction in adhesion forces and work exerted by wild-type mesendodermal progenitors, indicating the involvement of integrins expressed in these progenitors and the specificity of the detachment parameters recorded for fibronectin.[2]
GRGDSPK (RGD-containing, 1.5 mM, 1.0 mM, and 0.5 mM) and RGD-modified peptides, at concentrations of 1.5 mM, 1.0 mM, and 0.5 mM, impair the fertilization ability of bovine oocytes by sperm cells, resulting in a dose-dependent reduction in cleavage rates.[3] |
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 7.76 mg/mL (10 mM), Sonication is recommended.
|
| Keywords | βAmyloid | β Amyloid | GRGDSPK Acetate | BetaAmyloid | Beta Amyloid | bAmyloid | b Amyloid | amyloid-β peptides |
| Inhibitors Related | BSBM7 | Notoginsenoside R1 | Geniposide | Deferoxamine Mesylate | Tramiprosate | 20(S)-Ginsenoside Rg3 | PQM130 | Dihydroergocristine mesylate | Rutin | Human serum albumin | Methyl tridecanoate | Ginsenoside Re |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Anti-Alzheimer's Disease Compound Library | Peptide Compound Library | Bioactive Compounds Library Max |
United States
